

MEDICAL ONCOLOGY
PAPER-ITime: 3 hours
Max. Marks:100

MED.ONCO./J/20/17/I

Important Instructions:

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

- a) Goldie-Coldman hypothesis. 2+4+4
 - b) Dose density in chemotherapy.
 - c) Chemo-radiation.
- a) Clinical application of pharmacogenomics. 3+4+3
 - b) Potential applications of Artificial Intelligence in Oncology.
 - c) Phase 0 clinical trials.
- a) Clinical applications of massive parallel sequencing. 3+4+3
 - b) Testing for KRAS mutations in Oncology.
 - c) Epigenetics in cancer.
- a) Enumerate polyposis syndromes with risk of colon cancer. 2+4+4
 - b) Microsatellite instability.
 - c) Immunotherapy of colon cancer.
- a) Tumour mutation burden. 2+4+4
 - b) PERCIST 1.0.
 - c) Imaging of Neuro-endocrine tumours.
- a) Targeted agents as radio-sensitizers. 3+3+4
 - b) Antibody-drug conjugates.
 - c) Enumerate various approaches of immunotherapy with examples.
- a) Sunscreens in prevention of skin cancer. 3+4+3
 - b) Assessment of risk for hereditary breast cancer.
 - c) Hormonal prevention of breast cancer.
- a) Epstein-Barr virus and human cancer. 4+3+3
 - b) Hepatitis C and cancer.
 - c) Vaccines in prevention of cancers due to infections.

P.T.O

MEDICAL ONCOLOGY
PAPER-I

9. a) Targeted therapies that inhibit VEGF signaling. 4+3+3
b) Adverse effects of VEGF inhibitors.
c) Newer VEGF molecules available for therapy.
10. a) Imaging studies in diagnosis and staging of ovarian cancer. 4+3+3
b) Role of interim PET-CT scan in DLBCL treatment.
c) Tomosynthesis.

www.FirstRanker.com